

Leveraging the new Carterra **LSA<sup>XT</sup>**  
for challenging HT-SPR applications



# LSA accomplishments in just 5 years



- Redefined the scale of biotherapeutic characterization
- Core technology at 19 of top 20 pharma
- Published in high impact journals including Science, Nature, and Cell
- > 120 units deployed across the globe
- Part of Lilly's incredible 90 days to FIH
- Key for emerging AI/ML discovery strategies





# Meet the Carterra LSA<sup>XT</sup>



**Launched SLAS '23  
San Diego**



## Expanding on the LSA platform: Carterra LSA<sup>XT</sup>

100x the data | 10% the time | 1% the sample, *plus:*



Enhanced signal-to-noise



Increased signal uniformity



Faster data collection rate



| Application                                  | LSA | LSA <sup>XT</sup> |
|--|-----|-------------------|
| Purified or crude antibody kinetics/affinity | ✓   | ✓                 |
| Purified or crude epitope binning            | ✓   | ✓                 |
| Peptide mapping                              | ✓   | ✓                 |
| Mutant mapping                               | ✓   | ✓                 |
| Quantitation                                 | ✓   | ✓                 |
| General multiplexed binding                  | ✓   | ✓                 |
| Blockade assays                              | ✓   | ✓                 |
| DEL compounds                                | ✓   | ✓                 |
| Membrane proteins                            | ✓   | ✓                 |
| Peptides (analytes)                          |     | ✓                 |
| Cell therapy, e.g., TCRs                     |     | ✓                 |
| FcγRs  |     | ✓                 |
| Cytokines                                    |     | ✓                 |
| PROTACs/molecular glues                      |     | ✓                 |
| Kinase inhibitors                            |     | ✓                 |
| Thermodynamics                               |     | ✓                 |
| Protein:protein inhibition                   |     | ✓                 |



# LSA<sup>XT</sup>: Exploring smaller analyte formats using protein kinase inhibitors



## Assay conditions


- Six biotinylated kinases captured on SAD200M sensor chip in duplicate
- Injections of kinase antagonists prepared as three-fold dilutions starting from 3 $\mu$ M
- Assay buffer: HBS + 0.005% Tween20, 10 mM MgCl<sub>2</sub>, 3% DMSO, pH 7.4
- Temp: 15°C (increase protein life on the surface)





# Staurosporine: Expected profile of higher affinity but low selectivity


466.54 Da compound





# GSK-461364: Highly selective, high affinity PLK1 inhibitor

543.60 Da compound



## Value of LSA<sup>XT</sup> for affinity and selectivity screening

- Easily measure compounds down to at least 500 Da
- High capacity of array allows for a broad panel of targets and off-targets
- Both weak and high affinity interactions are readily quantitated



# Carterra LSA<sup>XT</sup>: PROTAC<sup>®</sup> characterization



# PROTAC assay design

- Running buffer: HBS + 0.005% Tween-20, 5% glycerol, 1 mM TCEP, 1% DMSO, pH 7.4
- Temp: 15°C (increase protein life on surface)
- Binary kinetics
  - His-bromodomain proteins and His-E3 ligases captured on a NiHC200M sensor chip, between 1 to 0.05ug/ml depending on the protein
  - MZ1 titration injected across array from 0.004 to 3uM
- Ternary kinetics
  - His-bromodomain proteins amine coupled to CMDP sensor chip
  - MZ1 titration injected in presence of  $\geq 20$ -fold molar excess of VHL across the array




# Assay format: Titrations of MZ1 +/- VHL against array of bromodomain proteins

Binary: MZ1 alone







OR

Ternary: MZ1+VHL




# Example of MZ1 binary kinetics including negative controls







# MZ1 binary kinetics against panel of bromodomain proteins



# Expected profiles for ternary complex formation




# MZ1/VHL ternary kinetics against array of bromodomain proteins




# Example of MZ1/VHL cooperativity towards BRD4 BD2

ternary interaction




binary interactions



$$\text{cooperativity} = \alpha = (K_D^{\text{binary}} / K_D^{\text{ternary}})$$

# Mapping cooperativity of >50 VHL/MZ1/bromodomain protein interactions



$$\text{cooperativity} = \alpha = (K_D^{\text{binary}} / K_D^{\text{ternary}})$$

## Key benefits of LSA<sup>XT</sup> for PROTAC characterization

- No labeling of reagents to confound binding interactions
- Direct and quantitative measurement of detailed kinetics for up to hundreds of interactions in parallel
- Flexibility to include controls, replicates, or different conditions all in a single run
- Minimal analyte sample requirements from the one-on-many fluidic design
- Bidirectional flow allows for extended injection contact times



# Takeaways

- Researchers now have two HT-SPR options depending on workflows and project needs
- LSA<sup>XT</sup> enables researchers to further expand the capabilities of HT-SPR
  - Rapid kinetics
  - Small analytes
  - Low signals



# Thank You!

Questions?

